Increase your Longevity
Live as Long as a Sequoia Tree
posted on Novemeber 24, 2009
Yes, we™re finally marching towards œimmortality.
I use that word loosely and in the sense that we should someday be immune from every disease and condition that currently kill us. We can worry about protecting ourselves from trauma as well, but nothing is forever, at least as far as I know.
Indefinite youth though, that™s our target. And we made huge strides at the Manhattan Beach Project Longevity Summit. A dozen world-class scientists disclosed how it will happen. We even found out when to expect amazing results (sooner than you might think). And then, four of the country™s top anti-aging physicians gave us hot tips on staying healthy until you can take advantage of these emerging technologies.
Finally, we fashioned a research budget that could let you live as long as a sequoia tree.
Exciting times to be alive, right?
In about two weeks, we™ll have all the presentations online for you to watch at your convenience. This is a $1200 value. That™s what people were willing to pay. It™s actually priceless. But you get it absolutely free!
Why? Because the more people who watch it, the more excitement we™ll generate, and the faster we™ll be able to raise the funds that need to be invested in this research. That means we™ll develop life-preserving technologies sooner, which in turn could put you on the youth restoration fast track.
Meanwhile, here™s a photo of most of the participants, including some brilliant business minds, who are developing fund raising strategies.
November 13-15, 2009; Manhattan Beach, CA; This three-day, invitation-only, 2009 Longevity Summit Conference cosponsored by the Maximum Life Foundation of Huntington Beach, CA and The Life Extension Foundation of Hollywood, FL held at the Marriott Hotel in Manhattan Beach, CA was attended by some of the smartest biogerontologists ever assembled in one place at one time, including Ray Kurzweil, Entrepreneur and CEO of www.AI.net; Stephen Spindler, Ph.D. of UC Riverside, Michael R. Rose, Ph.D. of UC Irvine; William Andrews, Ph.D., CEO of Sierra Sciences of Reno, NV; L. Stephen Coles, M.D., Ph.D. of UCLA, John Furber, CEO of Legendary Pharmaceuticals of Gainesville, FL; Michael West, Ph.D., CEO of BioTime of Alameda, CA; Gregory Fahy, Ph.D., VP of 21st-Century Medicine of Fontana, CA; Aubrey de Grey, Ph.D., CEO of the the SENS Foundation of Cambridge, UK; Peter Voss, CEO of Adaptive AI, Inc., Santa Monica, CA; Robert A. Freitas Jr., J.D., Senior Research Fellow for the Institute for Molecular Manufacturing of Palo Alto, CA; Ralph Merkle, Ph.D. Senior Research Fellow for the Institute for Molecular Manufacturing of Palo Alto, CA; Robert Bradbury, Pristine Stem Cells, Inc. of Cambridge MA; Michael Fossel, M.D., Ph.D., Michigan State University, East Lansing, MI; Karlis Ullis, M.D., of UCLA and Santa Monica, CA; Dr. Philip L. Miller, M.D., CEO of The Los Gatos Longevity Institute, Los Gatos, CA; Joseph Mercola, D.O., CEO of Mercola.com, David Woynarowski, M.D., CEO, "The Race Against Death"; David Kekich, CSO of the Maximum Life Foundation, Huntington Beach, CA [and Co-Chair]; and Neil Bodie, DVM, CSO of Trinity Therapeutics, Inc. of Agoura Hills, CA. Also: Noel Patton, CEO of TA Sciences in NYC; Greta Blackburn, Director of Marketing of TA Sciences in NYC [and Co-Chair]; Elena Kokurina of Science for Life Extension Foundation in Moscow, RUSSIA, Drs. Leonid Gavrilov and Natalia Gavrilova of the University of Chicago, Kevin Perrott. COO of the Lifestar Institute (CANADA), Ron Bailey of Reason Magazine, Kenneth Weiss; Bill Faloon, Co-founder Life Extension Foundation; Saul Kent, Co-founder Life Extension Foundation; Joe Sugarman, CEO Stem Cell Products, LLC; Mark Hansen of Mark Victor Hansen and Associates, Inc.; Stephen Vallentine; Oliver Luckett, Disney Executive; Wayne Allyn Root, 2008 Libertarian Party Vice Presidential Candidate; Richard Offerdahl, Biotech and Computer Businessman.
And here™s a summary article of our conference:
Did you exercise today? What did you eat? Are you doing all you can to add years to your life? Remember the prize! A little effort now could buy you all the time you™ll ever want to pursue anything you want.
Finally, here™s a free webcast brought to you by LifeStar Institute that could contribute to your health and longevity:
œA free public forum sponsored by the major Albertan institutions and communities involved and interested in the development of stem cell therapies as cures and treatments for degenerative disease.Â The forum is designed to engage the public in a focused dialogue to demystify stem cell therapies, their development, and application.
When: November 26th, 2009, 7:00 “ 9:30 PM
Where: Central Lions Center, 11113 “ 113 St, Edmonton, AB
LATEST HEALTHY LIFE EXTENSION HEADLINES
AN INTERVIEW ON CR WITH LUIGI FONTANA (November 20 2009) http://www.longevitymeme.org/news/vnl.cfm?id=4475
Here's a calorie restriction (CR) article I missed from earlier this month: "If anyone is in a position to assess the risks and benefits of CR, it is Dr. Luigi Fontana, research associate professor of medicine at Washington University. He is overseeing a group of 50 patients involved in an 11-year study of calorie restriction. The study is part of CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy), a large clinical trial being funded by the National Institute on Aging. Why is CR controversial in the United States? Dietitians seem opposed to this. First of all, probably most dietitians don't have knowledge about calorie restriction. These are pretty new data. Before they were only on mice and rats. So they say, 'OK, mice and rats, who cares about mice and rats?' And so this is a pretty new phenomenon, and any time there is a new phenomenon, there are a lot of people who say, 'No, no, no, no, no!' It's a typical reaction to something that is new. All the metabolic, hormonal and cellular adaptations so far we have seen in mice and rats, we know they are living longer, not only healthier but longer. We know that is also happening in monkeys and in humans."
BUILDING SKIN FROM STEM CELLS (November 20 2009) http://www.longevitymeme.org/news/vnl.cfm?id=4474
Researchers have succeeded in tissue engineering fully functional and complete skin patches from stem cells: the scientists recreated "a whole epidermis from human embryonic stem cells. The goal is to one day be able to propose this unlimited resource of cells as an alternative treatment in particular for victims of third degree burns and patients with genetic diseases affecting the skin. Human embryonic stem cells (hES) have two fundamental characteristics: a capacity for unlimited proliferation and pluripotency i.e. the capacity to differentiate into all the cell types in the human body. The first objective of the team was to obtain skin stem cells (keratinocytes) similar to those naturally present in the human epidermis from hES cells. Keratinocytes, permit the constant renewal of the skin. Once this stage was achieved, the second objective of the researchers consisted in finalizing strategies to isolate keratinocyte stem cells in order to test their capacity to reconstitute a functional epidermis firstly in vitro -- then in vivo. Twelve weeks after transplantation, the mice presented localized areas of completely normal and functional adult human epidermis containing all the skin cell types."
ACT AIMING FOR HUMAN STEM CELL TRIALS (November 19 2009) http://www.longevitymeme.org/news/vnl.cfm?id=4473
Advanced Cell Technology (ACT), one of the oldest companies formed specifically to develop regenerative medicine, is setting up for another round of human trials based on its work: "it has asked for approval to test human embryonic stem cells in treating a rare cause of blindness. The company said it filed an IND, an investigational new drug application, with the U.S. Food and Drug Administration to use the stem cells to treat patients with Stargardt's macular dystrophy. If approved, it would be the second U.S. approval to test human embryonic stem cells in human patients. ACT has previously reported it used human embryonic stem cells to make retinal cells. They have reversed blindness in rats. The treatment for eye disease uses stem cells to re-create a type of cell in the retina that supports the photoreceptors needed for vision. These cells, called retinal pigment epithelium (RPE), are often the first to die off in Stargardt's macular dystrophy. It has been over a decade since human embryonic stem cells were first discovered. The field desperately needs a big clinical success. After years of research and political debate, we're finally on the verge of showing the potential clinical value of embryonic stem cells. Our research clearly shows that stem cell-derived retinal cells can rescue visual function in animals that otherwise would have gone blind. We are hopeful that the cells will be similarly efficacious in patients."
AUBREY DE GREY ON CNN.COM, NOVEMBER 30TH (November 19 2009) http://www.longevitymeme.org/news/vnl.cfm?id=4472
From CNN: "This special edition of Vital Signs: The Clinic will be broadcast LIVE on CNN.com [on November 30th] and we want you to take part in the conversation. Vital Signs host and CNN Chief Medical Correspondent, Dr. Sanjay Gupta will be joined by best-selling author Dan Buettner who has done extensive studies on the areas in the world people live the longest, healthiest lives, known as Blue Zones, and shares their formula for a long life. The other panelist is geneticist Dr. Aubrey de Grey, who believes regenerative medicine could, in a matter of decades, extend life expectancy to 1000 years. What would you ask the experts? Do you want to learn how to live until 100 and beyond? Or find out which diets or exercise to follow for living longer?" These are good examples of the two very opposite ends of the respectable pro-longevity community. The Blue Zones material is (to be charitable) just a branding of what is known of the relationship between good health practices in diet and exercise and human longevity. Aubrey de Grey's Strategies for Engineered Negligible Senescence, on the other hand, are a serious examination of how to greatly extend healthy human life span through near-future research and development.
A PRESENTATION ON SUPERCENTENARIANS (November 18 2009) http://www.longevitymeme.org/news/vnl.cfm?id=4471
From the Age Management Medicine Group, a diagram-rich article based on a presentation given by one of the folk from the Supercentenarian Research Foundation: "A Supercentenarian is anyone age 110 years or older. While the number of centenarians has been rising exponentially, the number of supercentenarians has remained flat. The most likely cause of death of Supercentenarians is called Senile Cardiac TTR-Amyloidosis. SRF (Supercentenarian Research Foundation) has performed eight autopsies [of supercentenarians so far and six] of the eight cases have TTR-Amyloidosis as their common cause of death. This is the invisible barrier. Why do Supercentenarians live as long as they do? (How do they escape from chronic diseases, such as Heart Disease, Cancer, Stroke, Diabetes, and Alzheimer's Disease, which are the top diagnoses written today on Death Certificates in the US and limit the average life expectancy of older Americans?) Why don't they live longer than they do? (TTR Amyloidosis could be the Grim Reaper waiting in the wings for everyone, unless we figure out what to do about it first)."
EVALUATING AUTOLOGOUS STEM CELL HEART THERAPIES (November 18 2009) http://www.longevitymeme.org/news/vnl.cfm?id=4470
Even comparatively crude autologous stem cell transplants provide benefits for heart disease patients: "The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells. In the 12-month Phase II, double-blind trial, subjects' own purified stem cells, called CD34+ cells, were injected into their hearts in an effort to spur the growth of small blood vessels that make up the microcirculation of the heart muscle. Researchers believe the loss of these blood vessels contributes to the pain of chronic, severe angina. The stem cell transplant is the first therapy to produce an improvement in severe angina subjects' ability to walk on a treadmill. Twelve months after the procedure, the transplant subjects were able to double their improvement on a treadmill compared to the placebo group."
NOTE: Imagine the results if they got stem cells equivalent to teenage cells. This is on the horizon.
TRIAL OF A VIRAL CANCER THERAPY (November 17 2009) http://www.longevitymeme.org/news/vnl.cfm?id=4469
One class of the new generation of cancer therapies presently under development uses targeted viruses to kill cancer cells. Here is an example of the type: "BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study. [the therapy] is a first-in-class oncolytic, or cancer destroying virus, that works by replicating and spreading within solid tumors (leaving healthy cells unaffected), thereby causing cancer cell death and stimulating the immune system to destroy un-injected metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. Previous clinical trials have enrolled patients with breast cancer, melanoma, head and neck cancer and pancreatic cancer, with indications of clinical activity being observed in each. The Company recently commenced a Phase 3 study in metastatic melanoma." Therapies with few side effects and even low rates of success against metastatic cancer are a big deal. The success rate will only improve with time, and is already far greater than that of any presently widespread treatment option.
THOUGHTS ON REGENERATIVE MEDICINE (November 16 2009)
From the Times: "Over the past decade increasing understanding of both adult and embryonic stem cells has opened a new frontier for science through regenerative medicine. As research has revealed how the body's master cells can be coaxed to form new tissue, it has raised the prospect of producing new organs to replace those that have been damaged. Growing new cells with specialized functions, however, is only the first hurdle that has to be cleared before regenerative medicine can help patients. A clump of cells is rarely, by itself, much use to anybody. They also need to be properly plumbed into blood vessels, to be protected from the body's immune system and to be structured in a shape that allows them to perform. This means that regenerative medicine is not reliant only on the cell biologists who can coax stem cells to make the right sort of tissue. It also needs engineers and immunologists. It is by its nature an interdisciplinary field. As fast as this technology is advancing, however, there is still a long way to go before scientists can re-create more complex organs. Professor Hollander said: 'The early successes have involved organs without moving parts or complicated biology.' The creation of new breasts, windpipes and bladders is an amazing step forward for medicine, but it remains a different challenge to grow new hearts or livers."
TISSUE ENGINEERING THE BREAST (November 16 2009) http://www.longevitymeme.org/news/vnl.cfm?id=4466
From the BBC: "Researchers in Australia plan to test a medical 'scaffold' designed to stimulate natural breast tissue to regrow following surgery. Doctors [will] test the technique next year in a trial involving six patients. The team say that the permanent fat found in breasts can be grown inside this contoured scaffold. They claim to have successfully tested the device in pigs. When the 'empty chamber' is implanted, fat tissue will naturally fill it to form a new breast. This chamber will also contain a gel made using the patients' muscle cells to 'induce fat tissue production'. The attractions of this approach were its simplicity and the fact that the tissue growth occurred inside the body. At the time of implanting the cells the surgeon redirects the vasculature of the body which keeps a good blood supply to the implant. That is in itself nothing new, but combining it with a cell implant is an interesting step. The technological advance was the use of a biomaterial cage used to trap the cells in the right place. In future, the team plan to make this cage biodegradable so it does not have to be removed."